Business
PainReform Ltd. enters into a Strategic Investment Agreement to Expand its Non-Opiate Pain Management Pipeline into Opthamology with LayerBio
This Investment will add a differentiated ophthalmic platform, targeting an estimated 3 million annual U.S. cataract surgeries with long-acting, “dropless” pain and inflammation treatmentTEL AVIV, Israel, July 10, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX), today announced, through its pharmaceutical division, the signing of a strategic investment agreement with LayerBio Inc., a privately held Boston biotechnology company developing proprietary, long-acting, non-opiate treatments fo
About this update from Prf Technologies Ltd.
[{"type":"image","alt":"PainReform Ltd","displaySize":"","headline":null,"caption":"PainReform Ltd","className":"","disableSlideshowImg":false,"size":{"original":{"width":283,"height":122,"url":"https://media.zenfs.com/en/globenewswire.com/b87767806c4b38224443db9a93a3dd0a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8rnf4Sfc87De6ZQ.vLH_qw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b87767806c4b38224443db9a93a3dd0a","width":283,"height":122}},"lazy":false},{"type":"text","content":"This Investment will add a differentiated ophthalmic platform, targeting an estimated 3 million annual U.S. cataract surgeries with long-acting, “dropless” pain and inflammation treatment","length":187,"tagName":"p"},{"type":"text","content":"TEL AVIV, Israel, July 10, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX), today announced, through its pharmaceutical division, the signing of a strategic investment agreement with LayerBio Inc., a privately held Boston biotechnology company developing proprietary, long-acting, non-opiate treatments for ophthalmic surgery.","length":334,"tagName":"p"},{"type":"text","content":"This agreement marks PainReform’s plan to strategically expand into ophthalmology through the addition of a new drug delivery platform to its specialty pharma, non-opiate pain management pipeline. While the Company continues to advance its lead candidate, PRF-110, for the treatment of post-operative pain in general surgery, this strategic investment introduces a distinct and complementary technology targeting the high-volume cataract surgery market.","length":453,"tagName":"p"},{"type":"text","content":"LayerBio’s lead product candidate, OcuRing™-K, is a patent-protected, sustained-release intraocular ring designed to deliver anti-inflammatory and analgesic agents following cataract procedures. This “dropless” therapy has the potential to replace traditional post-surgical eye drops, which are often associated with poor absorption, low patient compliance, and ocular surface complications. With approximately 3 million cataract surgeries performed annually in the United States, OcuRing-K has the potential to address a significant clinical and commercial opportunity.","length":570,"tagName":"p"},{"type":"text","content":"Under the terms of the agreement, PainReform will receive a majority equity stake ...